Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented re... Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monoclonal antibodies, therapeutic molecules, small molecules, and fluids, improving dispersion and absorption. Key products include Hylenex recombinant for enhancing subcutaneous drug delivery in medical imaging and XYOSTED for testosterone replacement therapy via auto-injector. The ENHANZE drug delivery technology is licensed to partners for co-formulation in treatments targeting oncology, endocrinology, and other areas, with recent approvals for products like RYBREVANT FASPRO, DARZALEX Faspro, and collaborations such as with Takeda for vedolizumab. Halozyme Therapeutics Inc. also expanded its portfolio through the acquisition of Elektrofi, adding high-concentration biologic formulations via Hypercon technology. Operating primarily in the United States with international reach, the company supports biopharmaceutical partners in creating patient-friendly therapies that enhance convenience, tolerability, and adherence. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a vital role in advancing drug delivery innovations across therapeutic segments.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Halozyme Therapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Halozyme Therapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Halozyme Therapeutics's data?

Start your 30-day free trial to request a data review for Halozyme Therapeutics.

Start Free Trial

Legal Center Contact Us

Halozyme Therapeutics Inc

Halozyme Therapeutics is not subject to EU Taxonomy reporting

Account Restricted